In this issue:
Neurocognitive functioning in individuals at clinical high risk for psychosis
Suicide risk with schizophrenia across the life span
Reproductive safety of secondgeneration antipsychotics
ED presentations for schizophrenia during COVID-19 lockdown
Characteristics for discharge prescriptions for patients with schizophrenia or major depressive disorder
Early onset psychosis and cannabis use
Yoga therapy for social cognition in schizophrenia
Safety and effectiveness of lurasidone for schizophrenia
Perceptions of schizophrenia in the Australian community
Risk of mortality and complications in patients with schizophrenia and diabetes mellitus
Please login below to download this issue (PDF)